Ivo Sampaio-Dias

Dr. Ivo Sampaio-Dias

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2019 in Journal of Natural Products
Verified
Journal Article
Closed access
Margarida CostaMargarida Costa
Margarida Costa
ISIvo Sampaio-Dias
Ivo Sampaio-Dias
RCRaquel Castelo-Branco
Raquel Castelo-Branco
HSHugo Scharfenstein
Hugo Scharfenstein
RCRoberta Rezende de Castro
Roberta Rezende de Castro
PLPedro Leão
Pedro Leão

21 December 2020 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
ISIvo Sampaio-Dias
Ivo Sampaio-Dias
JRJosé E. Rodríguez-Borges
José E. Rodríguez-Borges
VYVíctor Yáñez-Pérez
Víctor Yáñez-Pérez
SGSonia Arrasate Gil
Sonia Arrasate Gil
JLJavier Llorente
Javier Llorente
Humbert G. DíazHumbert G. Díaz
Humbert G. Díaz

1 November 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JCJoana Ferreira da Costa
Joana Ferreira da Costa
OCOlga Caamaño
Olga Caamaño
FFFranco Fernández
Franco Fernández
XGXerardo García-Mera
Xerardo García-Mera
ISIvo Sampaio-Dias
Ivo Sampaio-Dias
MCMaría Isabel Cadavid
María Isabel Cadavid

3 February 2023 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
SSSara C. Silva-Reis
Sara C. Silva-Reis
ISIvo Sampaio-Dias
Ivo Sampaio-Dias
VCVera M. Costa
Vera M. Costa
XCXavier Cruz Correia
Xavier Cruz Correia
HCHugo F. Costa-Almeida
Hugo F. Costa-Almeida
JRJosé E. Rodríguez-Borges
José E. Rodríguez-Borges
Neurodegenerative diseases of the central nervous system (CNS) pose a serious health concern worldwide, with a particular incidence in developed countries as a result of life expectancy increase and the absence of restorative treatments. Presently, treatments for these neurological conditions are focused on managing the symptoms and/or slowing down their progression. As so, the research on novel neuroprotective drugs is of high interest. Glypromate (glycyl-L-prolyl-L-glutamic acid, also known as GPE), an endogenous small peptide widespread in the brain, holds great promise to tackle neurodegenerative diseases such as Parkinson's, Alzheimer's, and Huntington's, s well as other CNS-related disorders like Rett and Down's syndromes. However, the limited pharmacokinetic properties of Glypromate hinder its clinical application. As such, intense research has been devoted to leveraging the pharmacokinetic profile of this neuropeptide. This review aims to offer an updated perspective on Glypromate research by exploring the vast array of chemical derivatizations of more than 100 analogs described in the literature over the past two decades. The collection and discussion of the most relevant structure-activity relationships will hopefully guide the discovery of new Glypromate-based neuroprotective drugs.

3 November 2016 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
ISIvo Sampaio-Dias
Ivo Sampaio-Dias
CSCarlos Sousa
Carlos Sousa
XGXerardo García-Mera
Xerardo García-Mera
JCJoana Ferreira da Costa
Joana Ferreira da Costa
OCOlga Caamaño
Olga Caamaño
JRJosé E. Rodríguez-Borges
José E. Rodríguez-Borges
An efficient and straightforward orthogonal methodology was successfully developed to achieve constrained L-prolyl-L-leucylglycinamide (PLG) analogues starting from two proline mimetics based on a 2-azanorbornane scaffold. A preliminary dopamine D2 receptor radiolabeled binding assay with [3H]-N-propylnorapomorphine shows that enantiopurity of PLG peptidomimetics based on 2-azanorbornane is a requirement to achieve statistically significant positive modulators of the D2 receptor. This is the first documented active peptidomimetic of PLG whose bioactivity is not correlated with the C-terminal carboxamide pharmacophore and which cannot adopt the hypothesized type II β-turn conformation.

4 August 2017 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
ISIvo Sampaio-Dias
Ivo Sampaio-Dias
CSCarlos Sousa
Carlos Sousa
SSSara C. Silva-Reis
Sara C. Silva-Reis
SRSara Ribeiro
Sara Ribeiro
XGXerardo García-Mera
Xerardo García-Mera
JRJosé E. Rodríguez-Borges
José E. Rodríguez-Borges
This study describes a methodological advancement in solution-phase peptide synthesis via the development of a convenient and operational protocol to synthesize oligopeptides in a one-pot three-step cascade method, in which two peptide bonds are introduced chemoselectively. Tri- to hexapeptides were obtained in high global yields (80–95%) with virtually no epimerization as determined via HPLC. The methodology described herein represents a faster, easier and milder approach to the synthesis of peptides, and it operates at equimolar amounts. This protocol comprises the formation of secondary and tertiary amides and is compatible with Z, Boc and Fmoc N-protecting groups as well as the use of D/L and non-proteinogenic amino acids.